Brainstem auditory evoked response in newborns with hyperbilirubinemia.
OBJECTIVE
To determine the initial Brainstem Auditory Evoked Response (BAER) abnormalities in neonates with hyperbilirubinemia and the possible reversibility of abnormal BAER after therapy.


METHODS
Prospective cohort study.


METHODS
Tertiary care hospital.


METHODS
30 term neonates with hyperbilirubinemia (S. bilirubin < 15 mg/dl) as cases and 25 normal term neonates as controls.


METHODS
Duration of study was from August 1995 to August 1996. BAER were recorded before therapy at peak hyperbilirubinemia, after therapy, and the age of 2-4 months using electric response audiometer (Nihon Neuropack Four Machine). Denver Development Screening Test (Denver II) was performed at 1 year of age.


RESULTS
Seventeen out of thirty (56.7%) neonates with hyperbilirubinemia showed abnormalities on initial BAER. Commonest abnormality seen was raised threshold of wave V in 12 neonates (40%). Other abnormalities observed were absence of all waves at 90 dB (23.3%), prolongation of latencies of various waves (26.7%) and prolongation of various intervals (26.7%). Abnormalities in BAER correlated significantly with bilirubin level. After therapy abnormalities reverted back to normal in 10 cases but persisted in 7 out of 17 (41.17%) cases with initial abnormal BAER. Development screening at 1 yr was abnormal in 3 infants all of whom had persistent abnormalities in BAER.


CONCLUSIONS
Serial BAER is a useful, non invasive tool to detect neurodevelopment delay secondary to neonatal hyperbilirubinemia.
Agrawal
V K
VK
Department of Pediatrics, King George's Medical College, Lucknow.
Shukla
R
R
Misra
P K
PK
Kapoor
R K
RK
Malik
G K
GK
D001309:Auditory Threshold; D001663:Bilirubin / Q000097:blood; D016022:Case-Control Studies; D016057:Evoked Potentials, Auditory, Brain Stem; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000209:etiology* / Q000503:physiopathology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000097:blood / Q000150:complications* / Q000628:therapy; D008297:Male; D008403:Mass Screening; D011446:Prospective Studies
D001663:Bilirubin